JP2004536825A - 免疫疾患を治療する方法及び物質 - Google Patents
免疫疾患を治療する方法及び物質 Download PDFInfo
- Publication number
- JP2004536825A JP2004536825A JP2003506641A JP2003506641A JP2004536825A JP 2004536825 A JP2004536825 A JP 2004536825A JP 2003506641 A JP2003506641 A JP 2003506641A JP 2003506641 A JP2003506641 A JP 2003506641A JP 2004536825 A JP2004536825 A JP 2004536825A
- Authority
- JP
- Japan
- Prior art keywords
- compound
- administering
- galectin
- modified pectin
- animal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims description 58
- 239000000126 substance Substances 0.000 title abstract description 35
- 208000026278 immune system disease Diseases 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 47
- 229920001277 pectin Polymers 0.000 claims abstract description 42
- 239000001814 pectin Substances 0.000 claims abstract description 42
- 235000010987 pectin Nutrition 0.000 claims abstract description 42
- 102000007563 Galectins Human genes 0.000 claims abstract description 34
- 108010046569 Galectins Proteins 0.000 claims abstract description 34
- 230000028993 immune response Effects 0.000 claims abstract description 14
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims abstract description 8
- 229930182830 galactose Natural products 0.000 claims abstract description 8
- 102000000802 Galectin 3 Human genes 0.000 claims abstract description 7
- 108010001517 Galectin 3 Proteins 0.000 claims abstract description 7
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims abstract description 7
- 102000000795 Galectin 1 Human genes 0.000 claims abstract description 6
- 108010001498 Galectin 1 Proteins 0.000 claims abstract description 6
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical group C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 claims abstract description 6
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 claims abstract description 4
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims abstract description 4
- 108010038196 saccharide-binding proteins Proteins 0.000 claims abstract description 3
- 208000023275 Autoimmune disease Diseases 0.000 claims description 9
- 102000004169 proteins and genes Human genes 0.000 claims description 7
- 108090000623 proteins and genes Proteins 0.000 claims description 7
- 229920002230 Pectic acid Polymers 0.000 claims description 6
- 210000004027 cell Anatomy 0.000 claims description 5
- 239000010318 polygalacturonic acid Substances 0.000 claims description 5
- 229920000642 polymer Polymers 0.000 claims description 4
- 125000003396 thiol group Chemical group [H]S* 0.000 claims description 4
- 125000000089 arabinosyl group Chemical group C1([C@@H](O)[C@H](O)[C@H](O)CO1)* 0.000 claims description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 3
- 201000001320 Atherosclerosis Diseases 0.000 claims description 2
- 208000022461 Glomerular disease Diseases 0.000 claims description 2
- 229940100198 alkylating agent Drugs 0.000 claims description 2
- 239000002168 alkylating agent Substances 0.000 claims description 2
- 229910052798 chalcogen Inorganic materials 0.000 claims description 2
- 150000001787 chalcogens Chemical class 0.000 claims description 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 2
- 231100000852 glomerular disease Toxicity 0.000 claims description 2
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M thiocyanate group Chemical group [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 claims description 2
- 102000004190 Enzymes Human genes 0.000 claims 2
- 108090000790 Enzymes Proteins 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 abstract description 7
- 239000003814 drug Substances 0.000 abstract description 6
- 229920005615 natural polymer Polymers 0.000 abstract description 2
- 229920001059 synthetic polymer Polymers 0.000 abstract description 2
- 239000000463 material Substances 0.000 description 13
- 150000001720 carbohydrates Chemical class 0.000 description 8
- 235000014633 carbohydrates Nutrition 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 238000011282 treatment Methods 0.000 description 7
- 235000000346 sugar Nutrition 0.000 description 6
- 230000000694 effects Effects 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 3
- 230000000899 immune system response Effects 0.000 description 3
- 150000002772 monosaccharides Chemical class 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 2
- 230000002519 immonomodulatory effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 208000031295 Animal disease Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000009194 citrus pectin Substances 0.000 description 1
- 229940040387 citrus pectin Drugs 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000002715 modification method Methods 0.000 description 1
- 229940100657 nasal ointment Drugs 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 231100000925 very toxic Toxicity 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/732—Pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30036001P | 2001-06-22 | 2001-06-22 | |
| US10/176,022 US20030004132A1 (en) | 2001-06-22 | 2002-06-20 | Method and material for treating immune diseases |
| PCT/US2002/019886 WO2003000195A2 (en) | 2001-06-22 | 2002-06-21 | Method and material for treating immune diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004536825A true JP2004536825A (ja) | 2004-12-09 |
| JP2004536825A5 JP2004536825A5 (https=) | 2006-01-05 |
Family
ID=26871794
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003506641A Pending JP2004536825A (ja) | 2001-06-22 | 2002-06-21 | 免疫疾患を治療する方法及び物質 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20030004132A1 (https=) |
| EP (1) | EP1408989A2 (https=) |
| JP (1) | JP2004536825A (https=) |
| CN (1) | CN100558368C (https=) |
| BR (1) | BR0210547A (https=) |
| CA (1) | CA2451885A1 (https=) |
| IL (1) | IL159462A0 (https=) |
| WO (1) | WO2003000195A2 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040223971A1 (en) * | 2003-04-07 | 2004-11-11 | Glycogenesys, Inc. | Composition and uses of galectin antagonists |
| WO2004091634A1 (en) | 2003-04-07 | 2004-10-28 | Glycogenesys, Inc. | Composition and uses of galectin antagonists |
| WO2005058352A2 (en) * | 2003-12-17 | 2005-06-30 | Entelos, Inc. | Treatment of rheumatoid arthritis with galectin-3 antagonists |
| WO2005095463A1 (en) | 2004-03-26 | 2005-10-13 | Glycogenesys, Inc. | Modified pectins, compositions and methods related thereto |
| ES2750126T3 (es) | 2011-03-17 | 2020-03-25 | Critical Care Diagnostics Inc | Procedimientos de predicción del riesgo de un resultado clínico adverso |
| AU2012363033B2 (en) | 2011-12-28 | 2016-06-02 | Galectin Therapeutics, Inc. | Composition of novel carbohydrate drug for treatment of human diseases |
| ES2848538T3 (es) * | 2012-06-06 | 2021-08-10 | Galectin Therapeutics Inc | Composiciones de galacto-ramnogalacturonato para el tratamiento de enfermedades asociadas con elevada óxido nítrico sintasa inducible |
| DK2900061T3 (da) | 2012-09-17 | 2020-03-02 | Galectin Therapeutics Inc | Fremgangsmåde til forstærkning af specifikke immunterapier ved cancerbehandling |
| US8828971B2 (en) | 2012-10-10 | 2014-09-09 | Galectin Therapeutics, Inc. | Galactose-pronged carbohydrate compounds for the treatment of diabetic nephropathy and associated disorders |
| US9907814B2 (en) | 2012-12-20 | 2018-03-06 | Henry Ford Health System | Method for treating diastolic heart failure by inhibiting galectin-3 |
| US12390486B2 (en) | 2012-12-20 | 2025-08-19 | Henry Ford Health System | Method for treating diastolic heart failure by inhibiting galectin-3 |
| US9339515B2 (en) | 2013-02-20 | 2016-05-17 | Galectin Therapeutics, Inc. | Method for treatment of pulmonary fibrosis |
| CA3088736A1 (en) * | 2018-01-21 | 2019-07-25 | Rensselaer Polytechnic Institute | Method of treating galectin-3 dependent disorders |
| US20210138080A1 (en) | 2018-06-29 | 2021-05-13 | Glykos Biomedical Oy | Conjugates |
| US20230038373A1 (en) | 2019-12-18 | 2023-02-09 | Glykos Biomedical Oy | Stabile conjugate |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5490991A (en) * | 1986-07-03 | 1996-02-13 | Advanced Magnetics, Inc. | Directed delivery of radioprotectants using a receptor specific carrier |
| DE69118141T2 (de) * | 1990-06-27 | 1996-09-19 | Dainippon Ink & Chemicals | Alkyliertes oligosaccharid und acetylderivate davon |
| US5498702A (en) * | 1993-12-16 | 1996-03-12 | California Natural Products | Treated pectinic acid process and product |
| US5834442A (en) * | 1994-07-07 | 1998-11-10 | Barbara Ann Karmanos Cancer Institute | Method for inhibiting cancer metastasis by oral administration of soluble modified citrus pectin |
| US5831052A (en) * | 1997-05-07 | 1998-11-03 | Incyte Pharmaceuticals, Inc. | New human translocation associated protein |
| US6258383B1 (en) * | 1998-08-14 | 2001-07-10 | Lactoferrin Products Company | Dietary supplement combining colostrum and lactoferrin in a mucosal delivery format |
| US6500807B1 (en) * | 1999-02-02 | 2002-12-31 | Safescience, Inc. | Modified pectin and nucleic acid composition |
| US6680306B2 (en) * | 2001-06-21 | 2004-01-20 | Glycogenesys, Inc. | Method for enhancing the effectiveness of cancer therapies |
-
2002
- 2002-06-20 US US10/176,022 patent/US20030004132A1/en not_active Abandoned
- 2002-06-21 JP JP2003506641A patent/JP2004536825A/ja active Pending
- 2002-06-21 IL IL15946202A patent/IL159462A0/xx unknown
- 2002-06-21 CA CA002451885A patent/CA2451885A1/en not_active Abandoned
- 2002-06-21 EP EP02749642A patent/EP1408989A2/en not_active Withdrawn
- 2002-06-21 BR BR0210547-0A patent/BR0210547A/pt not_active IP Right Cessation
- 2002-06-21 CN CNB028160916A patent/CN100558368C/zh not_active Expired - Fee Related
- 2002-06-21 WO PCT/US2002/019886 patent/WO2003000195A2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| US20030004132A1 (en) | 2003-01-02 |
| BR0210547A (pt) | 2004-05-25 |
| CA2451885A1 (en) | 2003-01-03 |
| IL159462A0 (en) | 2004-06-01 |
| CN1543352A (zh) | 2004-11-03 |
| WO2003000195A3 (en) | 2003-03-20 |
| CN100558368C (zh) | 2009-11-11 |
| WO2003000195A2 (en) | 2003-01-03 |
| EP1408989A2 (en) | 2004-04-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004536825A (ja) | 免疫疾患を治療する方法及び物質 | |
| SK459890A3 (en) | USE OF HYALURONIC ACID, THE SALTS THEREOF AND ANALOGUES FORì (54) PRODUCING A THERAPEUTIC AGENT TO TREAT DISEASES OR CONDIT | |
| US8754043B2 (en) | Epidermal growth factor compositions | |
| RU2637443C2 (ru) | Проникающие через кожу композиции на основе гликозаминогликана для местного применения в косметических и фармацевтических целях | |
| US9982027B2 (en) | Control of rheological properties of mixed hyaluronate/lubricin solutions | |
| US20070141101A1 (en) | Method for stimulating angiogenesis and wound healing | |
| CN109803977A (zh) | 核酸产品及其施用方法 | |
| US20030013681A1 (en) | Method for enhancing the effectiveness of cancer therapies | |
| EP2670439A1 (en) | Active principle for mitigating undesired medical conditions | |
| EP2178565A1 (fr) | COMPLEXES ENTRE UN POLYMÈRE AMPHIPHILE ET UNE PROTÉINE OSTÉOGÉNIQUE APPARTENANT À LA FAMILLE DES BMPs | |
| JP2001504493A (ja) | 糖尿病の症状を治療する方法 | |
| HU230385B1 (hu) | Részlegesen deszulfatált glükóz-amino-glükánok származékai mint a heparanáz enzim inhibitorai, előállításuk és alkalmazásuk, valamint ilyen származékokat tartalmazó gyógyszerkészítmények | |
| KR101464208B1 (ko) | 당뇨성 신경병증에서 말초 신경의 형태기능의 복원을 위한 상피 성장인자의 용도 | |
| JP2007508250A (ja) | 持続性放出製剤における長期作用性分子 | |
| CA2519797C (en) | Low molecular weight hyaluronic acid for the treatment of nerve damage | |
| JP2022088630A (ja) | 潤滑性ブロックコポリマーおよび生体模倣境界潤滑剤としてのそれらの使用 | |
| JP2004536825A5 (https=) | ||
| EP1561760A2 (en) | Low molecular weight heparin salt with thriethanolamine | |
| JP2019528982A (ja) | 罹患椎間板の再生 | |
| JP2019196389A (ja) | 転移を阻害し、線維症を処置し、かつ創傷の治癒を向上させる方法および組成物 | |
| AU2002320141A1 (en) | Method and material for treating immune diseases | |
| EP3570874B1 (en) | Zwitterionic polymer-insulin compositions and related methods | |
| JP4889636B2 (ja) | 有機グルコサミン塩の使用 | |
| DE10324997A1 (de) | Mrp8/Mrp14 Inhibitoren und ihre Verwendung zur Prävention und/oder Behandlung von hypertrophen Narben und Keloiden | |
| Yu et al. | Replenishing Interfacial Lubrication: A Cartilage–Inspired Polyzwitterionic Dressing for Spatiotemporal Healing of Friction–Prone Diabetic Wound |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050614 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050620 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080801 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20081031 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20081110 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20081127 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20081204 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20090417 |